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Abstract 
 
Inadequate immunity that occurs in a tumor environment is in part due to the 
presence of M2-type tumor-associated macrophages (TAMs). TGF-β has a multi-
functional role in tumor development including modulating the biological activity of 
both the tumor and TAMs. In this study, using an in vitro TAM/tumor cell co-culture 
system ligation of TLR7, which is expressed on TAMs but not the tumor cells, in the 
presence of TGF-β receptor I inhibitor re-programmed the phenotype of the TAMs. 
In part they adopted the phenotype characteristic of M1-type macrophages, namely 
they had increased tumoricidal activity and elevated expression of iNOS, CD80 and 
MHC class II, while TGF-β secretion was reduced. The reprogrammed phenotype was 
accompanied by enhanced NF-κB nuclear translocation. The pro-angiogenesis factor 
VEGF was down-regulated and in vivo the number of CD31-positive tumor capillaries 
was also reduced.  Furthermore, in vivo we observed that TLR7 ligation/TGF-β 
receptor I inhibition increased tumor apoptosis and elevated the number of CD4+, 
CD8+, and CD19+ cells as well as neutrophils infiltrating the tumor. Our data 
demonstrate that selective TLR stimulation with TGF-β inhibition can reprogram 
TAMs towards an M1-like phenotype and thereby provides new perspectives in 
cancer therapy  
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1. Introduction 
Innate and adaptive immunity co-operate to protect the host from microbial 
invasion and tumor formation. However, recent data indicate that tumor associated 
immune cells including dendritic cells, regulatory T cells, macrophages and 
neutrophils may function both to protect and promote tumor progression [1, 7, 21, 
22]. The characterization of tumor associated macrophages (TAMs) has generated 
considerable interest. In lung, prostate and breast cancers and recently, Hodgkin’s 
lymphoma clinical studies have established a positive correlation between TAMs 
present in the tumor and poor prognosis [18, 30]. More recent reports have 
indicated that TAMs can protect tumor cells from chemotherapy [34]. In animal 
studies, the depletion of TAMs by Clodronate encapsulated in liposomes (clodrolip) 
[8, 33] or genetically modified IκB kinase β expression can reprogram the functional 
phenotype of TAMs [6, 11] leading to reduced tumor progression and prolonged 
survival.  These observations highlight the potential importance of targeting TAMs in 
tumor therapy. 
TAMs express the phenotypic characteristics of M2 macrophages [27] which 
differ from those of M1 cells (classical activated macrophages) [21]. They produce 
low levels of pro-inflammatory cytokines such as TNF-α, IL-6, and large amounts of 
the anti-inflammatory cytokines IL-10 and TGF-β. TAMs also express VEGF and 
promote both matrix formation and the activation of tumor related regulatory T cells, 
all of which promote tumor progression [29]. Previous studies have indicated that 
the polarization of TAMs can be modified by their environment. The combination of 
CpG and anti-IL-10 receptor antibody treatment of tumor bearing mice 
reprogrammed the phenotype of the tumor infiltrating macrophages to that of M1 
cells inducing TNF-α and IL-12 production and promoting tumoricidal adaptive 
immunity [9]. By altering the expression of intracellular signaling molecules such as 
STAT6, STAT3 and SHIP it has been demonstrated that the polarity of M2 cells can be 
changed [19]. However, it is not clear whether the changes are due to direct effects 
on TAMs or through changes in the microenvironment that alter the interaction 
between tumor cells and TAMs. More recent studies focused on the contribution of 
intracellular signaling pathways, such as c-MYC, in alternative activation of TAM 
activity [24]. TGF-β is an important growth factor in both the development of normal 
cells and tumor formation. Although it has been suggested that TGF-β functions in 
the prevention of tumor development during the early stages [28], in advanced 
tumors and in metastasis high expression of TGF-β is observed which correlates with 
the degree of malignancy. Consequently many anti-TGF-β treatments have been 
developed as potential tumor therapies [16]. The ability of TAMs to produce TGF-β 
[21] is well established for example in vitro altered TGF-β signaling mediated by 
expression of dominant-negative TβRII enhanced the tumor cytolytic activity of the 
macrophage cell line RAW [17]. Some studies illustrated the application of shRNA of 
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TGFβRII in reducing tumor metastasis [32]. However the contribution of TAM derived 
TGF-β in the tumor progression or in maintaining the M2 phenotype is ill defined. 
Angiogenesis is a vital process in tumor development and is the target of many 
anti-tumor therapies. TAMs are thought to help in angiogenesis through the 
production of VEGF and the subsequent increase in CD31 positive tumor capillaries 
[33]. Two trans-membrane proteins TIE-2 and NRP-1 appear to be essential for 
angiogenesis, both of which are expressed in tissue macrophages and play important 
roles in vessel formation through the downstream gene VEGF [5]. The expression of 
TIE-2 and NRP-1 in TAMs is low [25] but whether TGF-β has any effect on the 
expression of these two molecules is unknown. Determining if the reprogramming of 
the phenotype of TAMs also inhibits their ability to promote angiogenesis will 
provide information that may be useful in developing novel therapies. 
In brief, in this study, we have characterized the phenotype of TAMs isolated 
from fibrosarcoma cells stimulated with TLR ligands in the presence of specific TGF-β 
receptor I (TβRI) inhibitors. We report that TLR7 ligation in the presence of TGF-β 
inhibition in vitro re-programs TAMs to M1 cells and reduced their ability to produce 
angiogenesis promoting factors in macrophage/tumor cell co-cultures.  In vivo 
treatment increased the tumoricidal activity 
of the TAMs and reduced tumor progression.  
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2. Materials and methods 
2. 1  Mice and reagents 
Inbred male C57BL/6 mice (6-8 weeks old) were used.  The experimental protocol 
was approved by the Committee on the Use of Live Animals in Teaching and 
Research, the University of Hong Kong. SB432542 was purchased from Tocris 
Bioscience, Bristol, UK; Rat anti-mouse CD11b, Rat anti-mouse CD11c, TGF-β Elisa kit 
was from BD Bioscience, San Jose, CA; Dispase I was from Roche Applied Science, 
Penzbeg Germany; DNase I was from Invitrogen, Carlsbad CA; Gardiquimod™, 
ODN1585, were from Invivogen, San Diego, CA; LPS (Salmonella), N-Acetylmuramyl-
L-alanyl-D-isoglutamine hydrate (MDP) and SB505124 were from Sigma-Aldrich St. 
Louis, MO; Antibodies: rabbit anti-mouse F4/80 biotin-conjugated, CD4, CD8, CD19 
antibodies, Elisa kit for TNF-α, IL-10 and IL-12 P40 were from BioLegend, San Diego, 
USA. Rat anti-mouse neutrophils antibody was purchased from ABCAM, MA, USA. 
Phoenix-Eco packaging cells were obtained from GENTAUR Europe, Kampenhout, 
Belgium. Rabbit anti-mouse NF-κB (P65) was from Santa Cruz, CA, USA 
 
 
2. 2  Mouse fibrosarcoma tumor model and TAMs isolation and culture  
Mouse fibrosarcoma model was established by intramuscular injection of 1x105 
MN/MCA1 cells into caudal thigh muscle as previously described [26]. Tumor mass 
was removed three weeks later. The tumor tissue was digested with Dispase I 
(2.4U/ml) with DNase I (25μg/ml) for 10 minutes with constant agitation at 37C. The 
mixture was filtered through nylon mesh and further purified with F4/80 biotin-
conjugated antibody together with anti-biotin microbeads. The purity of TAMs 
was >95% as determined by CD11b+CD11c- staining and measured by flow 
cytometry.  Then isolated TAMs were cultured in RPMI medium with 10% FBS at 
37ºC in 5% CO2 before treatment. 
 
2. 3  Histology and Immunohistochemical analysis 
4μm frozen or paraffin sections were cut and stained with Haematoxylin & Eosin. 
Immunohistochemical analysis was performed by cold acetone fixation, endogenous 
peroxidase blocking solution (Dako Corp. Carpinteria, CA) and 10% goat serum to 
prevent non-specific binding. The sections were incubated with primary antibodies 
for 16 hours at 4C and the signals were detected with a DAKO EnVisionTM+ System. 
Rat anti-mouse antibodies specific for CD4(1:100), CD8(1:100), F4/80(1:200), 
CD31(1:200) and neutrophils(1:100) were used in the experiments.  
 
2. 4  Transfection of luciferase into MN/MCA1 
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MN/MCA-Luc cells were generated by retroviral transduction. To prepare 
pMIGR.Luc retroviral constructs, the full length luciferase gene was excised from 
pGL3 vector between BglII and BamHI sites and cloned into pMIGR retroviral vector 
at the BglII site. The pMIGR.Luc constructs were then transfected into Phoenix-Eco 
packaging cells with lipofectamine™ for synthesis of retroviral supernatants. 
Supernatants were collected on day 2 post-transfection. For retroviral transduction, 
MN/MCA cells were cultured with 50% (v/v) of the retroviral supernatant in the 
presence of polybrene (8μg/ml) at 37ºC for 24 hours. Culture supernatants were 
then removed and replaced with fresh medium. GFP-luciferase positive cells were 
isolated by cell sorting. 
 
2. 5  Quantitative -PCR 
The total mRNA was isolated with TRIZOL®. Q-PCR was performed according to 
manufacturer’s instructions. Briefly, RNA was reversed transcribed random primer 
and SuperScript II reverse transcriptase (Invitrogen Corp). PCR was performed using 
Taq polymerase (Applied Biosystems) with the SYBR® Green-Based Detection system. 
Relative quantification of mRNA expression was normalized with control GAPDH and 
analyzed using the Delta Delta Ct (2-ΔΔCT) method. Primers sequences 
(Forward/Reverse): Ym-1: gcataccttt atcctgagtg acc/gacattgtca taaccaaccc actc; iNOS: 
gccgtggcca acatgctact/ ggtcttccrg ggctcgatct g; TLR4: tgacaccctcc atagacttc/ tgcttctgtt 
ccttgaccca c; TLR7: ggacctcagc cataaccagc/cccaccagac aaaccacaca gc; TLR9: 
atcgcatcag tgggccttca acg/ggcaggaact gagagccatt gac; NOD2: gtgctttttt gccgctttct 
acttgg/ttcttgactc tggagccctg gatac. VEGF: gctactgccg tccgattgag a/ ggtgaggttt 
gatccgcatg a; NRP1: gatgagtgtg acgacgacca ggcca/tcccagtggc agaatgtctt gtgag. 
 
2. 6  Western blot analysis 
10g protein were denatured and separated by electrophoresis. Proteins were 
electro-transferred onto PVDF-membranes and then blocked with TBST with 5% low-
fat milk. This was followed by an overnight incubation at 4C with anti-TRAF6 and 
anti-NF-κB antibodies (1:1000) and further incubated with a horseradish peroxidase 
(HRP)-conjugated secondary antibody. The signals were developed using ECL chemi-
luminescence (Amersham). The membrane was then stripped and reprobed with 
anti-actin antibody.  
 
2. 7  ELISA measurement cytokines expression 
The secreted cytokines in the culture supernatants were measured by ELISA 
according to manufacturer’s instructions. In order to measure the total 
concentration of TGF-β, supernatants were acidified. All the measurements were 
 7 
 
made in triplicate and minimum 2 sets of independent experiments for each 
treatment were performed. 
 
2. 8  Flow cytometry 
The cell surface activation markers CD40, CD86, MHC class II and CD80 were 
analyzed using flow cytometry. After tissue digestion or cell culture, single cell 
suspensions were labeled with antibodies and analyzed by flow cytometry. 
Appropriate isotype-matched IgGs were used as negative controls. 
 
2. 9  Luciferase activity measurement 
For testing the tumoricidal activity of TAMs in response to the different 
treatment regimens, 1x105 cells (TAMs) were co-cultured with 2,500 MN/MCA1-Luc 
for 3 days. The luciferase activity was measured using Dual-Luciferase® Reporter 
Assay System (Promega) with MicroBeta® TriLux β-counter (Perkin Elmer, MA). Each 
sample was performed in triplicate and the averages of each point were calculated.  
 
2. 10  In vivo analysis of biological effects of TLR7 ligation together with TGF-β 
inhibition on tumor progression  
The tumor model used here has been described previously (Section 2.2). In brief, 
1x105 MN/MCA1 cells were injected in caudal thigh muscle. SB505124 was dissolved 
in DMSO then further in PBS and the Gardiquimod in PBS. Less than 30μl of DMSO 
was injected intraperitoneally in mice and the vehicles alone were used as control 
groups. The treatment was initiated 3 days after tumor cell inoculation and 
continued for 2 weeks with delivery on alternative days. At end of treatment, the 
tumor size was analyzed by an IVIS imaging system (PerkinElmer, MA, USA) and 
photographed. The mice were then sacrificed and the tumors were isolated for 
further analysis by immunostaining.  
2. 11  Tunnel assay 
The tissue apoptosis was evaluated by using In Situ Cell Death Detection Kit 
Fluorescein (Roche Diagnostics (Hong Kong) Ltd) following the manufacturer’s 
instructions. The immuno-fluorescent signals (Annexin-V-FITC) were detected with 
Nikon 80i fluorescent microscope and photographed. DAPI was used for control 
nuclear staining. 
2. 12  Statistical analysis 
All the data here are presented as means±SEM. In order to determine statistical 
significance results were analyzed with the Student paired t test when two sets of 
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data were compared or one way ANOVA for the comparison of three set of data. 
Bonferroni's Multiple Comparison Test was used to compare the difference among 
the groups. p<0.05 was considered significant. The data were collected and analyzed 
using GraphPad Prism software (GraphPad Software, Inc., CA). 
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3. Results 
3. 1  Effect of tumor supernatants on TGF-β1 and TNF-α biosynthesis by TAMs 
In order to test the effects of microenvironmental changes on the function of the 
TAMs they were cultured with tumor derived supernatants (50% v/v) in the presence 
and absence of LPS and TGF-β1 and TNF-α production was measured (Fig.1A). In the 
untreated TAM cultures only basal levels of TGF-β1 were detected which remained 
unaltered by the addition of the tumor supernatants. Stimulation with LPS at 10 and 
200ng/ml only minimally enhanced TGF-β1 production. However, the addition of 
tumor supernatants reduced TGF-β expression in LPS stimulated TAMs to below 
basal levels (from 344pg/ml to 37pg/ml, p<0.05). Regarding TNF-α, the basal levels 
recorded in the absence of LPS stimulation was slightly reduced by exposure to the 
tumor supernatants. LPS stimulation increased TNF-α production which was 
significantly reduced following the addition of the tumor derived supernatants (Fig 
1A). Similarly, IL-10 and IL-12 P40 secretion was also reduced in response to TS 
treatment. These results suggest that the tumor microenvironment can modulate 
TAM activity as regards cytokine expression. In subsequent experiments, therefore, 
tumor supernatants were added to replicate some aspects of in vivo conditions. 
 
3. 2  Effects of TGF-β receptor I inhibitors on TAM function 
TGF-β signaling was blocked by the addition of the TGF-β receptor I inhibitor, 
SB431542 (SB4x) and the effects on tumoricidal activity were examined after 3 days. 
Exposure to LPS in the presence and absence of SB4x had no obvious effects on TAM 
morphology compared to the control cultures (Fig.1B). However, when TAMs were 
co-cultured with tumor cells (TAM:MN/MCA1=10:1) and stimulated with LPS there 
was a slight inhibition of tumor cell growth. The phenomenon was more marked 
when LPS and SB4x were both present in the co-cultures as most of the cells died 
(Fig.1B).  
 
3. 3  Expression of pattern recognition receptors  
Since the tumoricidal effect was minimal when the ratio of TAMs to MN/MCA1 
was reduced to 3:1 we investigated whether it could be increased by enhanced 
activation of the TAMs. Macrophage activation can be achieved by ligation of pattern 
recognition receptors (PRR) such as Toll-like receptors (TLRs) or Nod-like receptors 
(NODs). The expression of TLR4 on tumor cells can aid escape from immune 
surveillance and increase resistance to apoptosis [12, 13]. Therefore, PRR expression 
was compared on MN/MCA1 and TAMs in order to identify a receptor that was 
present on TAMs but absent or reduced on MN/MCA1 cells thereby allowing 
activation of the TAMs but not the tumor cells when stimulated with the appropriate 
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ligand.  The levels of specific transcripts for TLR4 and NOD2 were similar in both 
MN/MCA1 cells and TAMs. However, there were major differences in the expression 
of TLR7 and TLR9, which were present at very low levels in the MN/MCA1 cells 
compared to TAMs (Fig.2A). Following stimulation with appropriate ligands the 
expression of TLR4, 7, 9 and NOD2 was measured in the presence and absence of 
SB505124 (SB5x), a TGF-β receptor I inhibitor which is 5 fold more potent than its 
analogue SB4x [2]. TLR4 and NOD2 expression was slightly reduced by treatment 
with specific ligand or ligand plus SB5x compared to the untreated co-cultures. 
Transcripts for TLR9 were increased following stimulation with ODN1585 but 
remained unchanged when SB5x was added. The ligation with Gardiquimod had 
minimal effect on TLR7 expression but in the presence of SB5x treatment expression 
was markedly increased (Fig.2B). 
 
3. 4  Effects of TLR7 stimulation together with TGF-β inhibition on the phenotype 
of TAMs 
The effects of TLR7 ligation on TAM tumoricidal function were investigated. 
Tumor cells transfected with luciferase (MN/MCA1-Luc) were used as target cells to 
allow quantitation of the killing activity.  Compared to the untreated control group of 
tumor cells alone the addition of Gardiquimod, SB5x or two together has no obvious 
effects on tumor cell proliferation since similar luciferase activity was observed in all 
these conditions (Fig.3A). However, when the tumor cells were co-cultured with 
TAMs in the presence of Gardiquimod alone tumor cell proliferation was reduced by 
40% (p<0.01). Similarly the addition of SB5x alone also reduced tumor cell 
proliferation but it was less marked than that of Gardiquimod (p>0.05). The effect 
was further enhanced when SB5x and Gardiquimod were added together (70% 
inhibition, p<0.001; Fig.3A MN+TAM). 
As regards cytokine production TGF-β was significantly reduced in co-cultures 
treated with Gardiquimod and SB5x compared to the controls (p>0.05) and in 
contrast, TNF-α was slightly increased but was not statistically significant (Fig.3B). 
Combined treatment with Gardiquimod and SB5x resulted in an up-regulation of 
iNOS mRNA (p<0.01) and down-regulation in the expression of Ym-1mRNA (p<0.001) 
in the co-cultures (Fig.3C). Furthermore, cell surface expression of MHC class II and 
CD80 was elevated in the combined treatment versus Gardiquimod treatment alone 
(Fig.3D).  
 
3. 5  The effects of TLR ligand/TGF-β inhibitor treatment on intracellular signaling  
A notable difference of M2 and M1 cells is their NF-κB activity, which is reflected 
in enhanced expression of the p65 intra-nuclear activity of the NF-κB subunit [10]. 
Therefore intracellular expression of TRAF6 and NF-κB were examined in order to 
determine if the level of intracellular signaling changes in TAMs in response to TLR 
 11 
 
ligand/TGF-β inhibitor treatment. For TRAF6, there was a modest increase in 
expression induced by Gardiquimod which was further elevated by the addition of 
the TGF-β inhibitor. A similar outcome was observed for NF-κB expression (Fig.4A). 
NF-κB expression and the nuclear translocation were examined in the co-cultures 
and compared to the untreated control treatment with Gardiquimod and SB5x 
greatly increased the expression of NF-κB with enhancement of nuclear expression 
(Fig.4B).  
 
3. 6  In vivo effects of TLR7 ligation and TGF-β inhibition on tumor progression 
In this set of experiments we investigated if treatment with Gardiquimod and 
SB5x reduced tumor growth in vivo.  Tumors were established by MN/MCA1 
inoculation for 2 days and then the compounds were delivered by intra-tumoral 
injection. Compared to the control group Gardiquimod and SB5x treatment greatly 
increased tumor apoptosis as demonstrated by TUNEL (Fig.5a). Analysis of the 
cellular infiltrate by flow cytometry revealed an increase in CD4+, CD8+ and CD19+ 
cells in the treated mice (Fig.5b). In addition within the tumor mass there was an 
increase in CD11b+ cells which expressed higher levels of MHC class II and CD86, 
although the total number of CD11b+ cells was slightly reduced (data not showed). 
Immuno-histochemical studies confirmed the increase in CD4+ and CD8+ cells. We 
also detected increased numbers of neutrophils, but the number of TAMs was 
slightly reduced (Fig.5C). The inhibition of tumor progression was determined by in 
vivo luciferase activity imaging and when compared to the untreated group 
treatment with SB5x and Gardiquimod markedly reduced the tumor size (Fig.5D).  
 
3. 7  The effects of TLR7 ligation and TGF-β inhibition on angiogenesis  
A characteristic of TAMs is their ability to promote tumor angiogenesis. 
Therefore, we investigated the effects of TLR7 ligation/TGF-β receptor 1 inhibition on 
the expression of NRP-1 and VEGF mRNA. In TAMs plus MN/MCA1 co-cultures, 
Gardiquimod alone reduced NRP-1 expression however when both compounds were 
delivered there was no significant down-regulation (Fig6A). In contrast, Gardiquimod 
treatment alone had no effect on VEGF expression whereas SB5x alone and Grad 
plus SB5x significantly reduced its expression. In parallel in vivo we stained for CD31+ 
cells and observed that the number of CD31+ cells in the tumor capillaries in 
combination treated group was greatly reduced (44.6%, p<0.001). 
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4. Discussion 
TGF-β1 can be detected in tumor tissue [4] isolated from both cancer patients 
and experimental animal tumor models [23]. Here we have examined the regulation 
of TGF-β1 production by TAMs that occurs following their interaction with 
fibrosarcoma (MN/MCA1) tumor cells in vitro. Our results demonstrated that TAMs 
alone expressed low levels of activated TGF-β1 which were unaffected by the 
addition tumor cell derived supernatants. Activated TGF-β was increased after LPS 
stimulation but this response was reduced in the presence of tumor supernatants. 
Thus the tumor microenvironment seems to be important in regulating TGF-β 
production even in the presence of TLR mediated activation. For the mouse 
MN/MCA1 cells TGF-β was not essential for their proliferation as the TGF-β inhibitor 
had no effect suggesting that TGF-β1 production may be primarily regulating TAMs 
activity. TNF-α is effective in tumor killing [3] but recent findings suggest that it may 
also promote tumor metastasis[14]. Here we observed that the basal production of 
TNF-α by TAMs was low but was greatly increased by LPS stimulation. However, in 
the presence of the tumor derived supernatants this LPS mediated induction of TNF-
α was significantly reduced. The effect of the tumor supernatants which in part 
mimic the tumor microenvironment indicates that TAMs activity is modulated by the 
tumor cells. It has been reported that tumor supernatants promote myeloid-derived 
suppressor cell (mainly macrophages) production of VEGF and bFGF resulting in 
enhanced angiogenesis[15]. Our results are in agreement, in the context that some 
tumors can produce factors that are capable of altering macrophage function.  
The effect of TGF-β signaling on the phenotype of TAMs was investigated in the 
presence of TGF-β receptor 1 inhibitors. Exposure to LPS or LPS together with SB4x 
had no obvious effects either on tumor cell proliferation or TAM morphology (data 
not shown). However, in the TAM/tumor cell co-cultures the addition of LPS and 
TGF-β inhibitor resulted in reduced tumor cell growth. It has been suggested that 
macrophages with characteristics of M1 cells display tumoricidal activity when 
activated with LPS [20]. Our data here suggest that it is possible to partially reverse 
the phenotype of the TAMs towards that of M1 type macrophages. However, in vitro 
the tumoricidal effect was limited at reduced ratios of TAMs to MN/MCA1 cells. It 
has been suggested that the expression of TLR4 in tumor cells reduces apoptosis [12], 
which prompted us to look for other ways of amplifying the response of the TAMs 
without activating the tumor cells. We observed that basal expression of TLR7 and 9 
was much lower in MN/MCA1 cells than in the TAMs.  In TAM/tumor cell co-cultures 
stimulation with TLR7 specific ligand in the presence of TGF-β inhibitor the 
expression of TLR7 was markedly elevated.  The combination of TLR7 signaling and 
TGF-β blockade also inhibited tumor cell proliferation, reduced TGF-β expression, 
increased iNOS expression and lowered that of Ym-1 in the TAMs.  Both MHC class II 
and CD80 were up-regulated suggesting that the treatment both activates and 
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reprograms TAMs towards the M1 phenotype which would favor the induction of 
anti-tumor adaptive immunity.  
It has previously been reported that NF-κB signaling is reduced in TAMs but can 
occur in the presence of STAT1 implying a functional IFN-β/IFN-γ pathway. 
Furthermore, TGF-β1 is negative regulator of TLR4 and MyD88. The inhibition of TGF-
β signaling together with TLR7 stimulation increased NF-κB activation through the 
up-regulation of TRAF6 and increased translocation of NF-κB. However, the failure to 
detect the early phase of MKK activation after stimulation with LPS and the TGF-β 
inhibitor suggests that the reprogramming towards to a M1 phenotype, induced by 
TLR7 ligand stimulation, is only partial.  
In order to establish proof of principle that TAM reprogramming can occur in vivo 
and prevent and/or reduce tumor progression mice were treated with the 
combination of SB5x and TLR7 ligand.  This resulted in the reprogramming of an M1 
phenotype in the TAMs and marked killing of the tumor cells in vivo. The reduction in 
tumor cells may be partly due to an increase in the number of inflammatory cells 
infiltrating the tumor. This implies that the immunosuppressive effect of the TAMs is 
diminished perhaps as the result of reduced of TGF-β production and increased MHC 
class II expression. Furthermore, the combination treatment also reduced the ability 
of TAMs to promote angiogenesis. It has been reported that TGF-β1 stimulates VEGF 
expression via MKK3 and activation of p38α and p38δ MAPK-dependent pathway in 
murine mesangial cells [31]. The reduction in TGF-β1 expression will have a direct 
effect on VEGF synthesis. Here we observed no TIE-2 expression (data not shown) 
and the basal expression levels of NRP-1 were not affected by TGF-β inhibition 
suggesting in TAMs that VEGF expression may be more related to TGF-β signaling 
than TIE-2 and NRP-1.  
The results also revealed that the balance of tumor cell proliferation and 
tumoricidal activity of reprogrammed TAMs was altered.  At early time points 
treatment effectively controlled tumor growth however, if it commenced on day 7 
after tumor cell inoculation the effect was minimal. This outcome may due to a large 
tumor burden in vivo since we observed in the in vitro studies that with higher 
numbers of tumor cells (i.e. TAM/tumor cell ratios of 1:3) the tumoricidal effect was 
limited. Similar observations were reported following with anti-IL-10 antibody and 
CpG treatment where the minor effect on tumor progression could be potentiated 
by adding CCL16 to recruit more DCs or macrophages to the tumor [9]. In agreement 
with that we have observed that treatment together with low dose of cisplatin 
(1mg/kg) enhanced tumor killing (data not showed) which confirms that 
reprogramming TAMs may facilitate tumor treatment.  
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In summary our results demonstrate that TLR mediation signaling in combination 
with TGF-β inhibition can partially reprogram TAMs to a M1 phenotype and reduce 
tumor progression in vitro and in vivo in this mouse model of fibrosarcoma. 
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Figures legends 
Figure 1: Effects of tumor supernatant on TAM cytokines expression and TGF-β 
inhibition on the modulation of TAMs phenotype 
1A Effects of tumor cell derived supernatants on TGF-β, TNF-α, IL-10 and IL-12 
production. TAMs (1x106/well) were cultured in 2ml RPMI medium with 10% FBS 
alone (RPMI full) or with medium supplemented with 50% (v/v) tumor cell culture 
supernatant (TS). Tumor culture supernatants were harvested from tumor cell 
cultures after 3 days. Levels of TGF-β, TNF-α, IL-10 and IL-12 P40 in TAMs cultures 
were measured by ELISA. LPS10, LPS200 indicated LPS at concentrations of 10ng/ml 
and 200ng/ml respectively. p<0.05 n=4 compared to no tumor supernatant added 
group. 1B TAMs were isolated from mice inoculated with tumor cells (MN/MCA1) for 
three weeks. Cells (1x106/wells) were cultured in medium with tumor supernatants 
alone or with tumor cells (1x105/wells) in the presence of LPS (10ng/ml) or LPS+SB4x 
(10μM) for 3 days and the cells photographed. (n=4) 
 
Figure 2: Expression of TLR4, 7, 9 and NOD2 in TAM and tumor cells and changes in 
their expression in response to the ligands 
2A Untreated TAMs, tumor cells and 2B Co-cultures of TAMs and tumor cells 
(MN/MCA1) in the presence of respective TLR4 ligand LPS (10μg/ml), TLR7 ligand 
Gardiquimod (5μg/ml), TLR9 ligand CpG (5μg/ml) or NOD2 ligand MDP, 1μg/ml) with 
and without TGF-β inhibition (SB5x, 5μM) were harvested after 24hrs and specific 
transcripts for TLR4, 7, 9 and NOD2 were measured by Q-PCR. Each experiment was 
performed in triplicate and at least two independent experiments were performed. 
The p value for the statistical significance is indicated in the graph. 2C Western blot 
analysis of the expression of TLR4 and TLR7 in TAMs and MN/MCA1 cells (n=2, one 
representative experiment is presented).  
 
Figure 3: Effect of the TLR7 ligand Gardiquimod on modulating TAM gene 
expression and activation 
3A MN/MCA1-Luc (2,500/well, MN, left) or MN/MCA1+TAMs (2,500+1x105, 
respectively, MN+TAM, right) were cultured in 96 wells culture plate in the presence 
of Gardiquimod (Gard, 5μg/ml), SB5x (5μM) and Gard+SB5x for three days and the 
luciferase activity were measured. Each treatment was triplicate and the average 
was shown. 3B Levels of TGF-β and TNF-α biosynthesis in TAMs (3.8x105/well) alone 
or co-cultured with MN/MCA1 (3.8x104/well) in the presence of Gardiquimod, SB5x 
or together (same concentration as mentioned above). Supernatants were collected 
after 24hrs and cytokine levels measured by ELISA. 3C Expression of iNOS and Ym-1 
mRNA in the presence of Gardiquimod +/- SB5x was measured after 4 hr of 
treatment by Q-PCR. 3D Cell surface expression of CD40, CD80, CD86 and MHC class 
II was measured by flow cytometry after 24hrs treatment with Gardiquimod 
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together with TGF-β inhibition and the mean fluorescent intensity (MFI) was shown. 
n=3 in each data sets and the p value for the statistical significance is indicated in the 
graph 
 
Figure 4 Modulation of intracellular signaling in response to LPS or Gardiquimod in 
presence of TGF-β inhibition 
4A The TAMs were treated with LPS (10μg/ml), LPS with SB5x (5μM), LPS+SB5x, 
Gardiquimod (Gard, 5μg/ml) or Gardiquimod with SB5x (Gard+SB5x) for 24hrs. The 
protein was extracted for western blotting. n=3 and one representative was shown. 
4B For the NF-κB translocation assay cells were treated with Gardiquimod with SB5x 
(same concentration as above) for 30min and fixed in 4% paraformaldehyde for 10 
min, followed by immunohistochemical staining of NF-κB p65 and compared to 
untreated group. Nuclear position was determined with DAPI staining. Green Arrow 
showed the nuclear expression of NF-κB in TAMs 
 
Figure 5: In vivo analysis of Gardiquimod and TGF-β blockade on tumor progression 
5A TUNEL assay. H-E staining; FITC-labelled annexinV and DAPI staining for nuclear 
location in tissue sections. 5B Analysis of tumor infiltrate. The tumor mass was 
removed and single cell suspension prepared. Cells were stained for CD4, CD8, CD19 
and TAMs were stained with CD11b, CD86 and MHC Class II then analyzed by flow 
cytometry. 5C Immunohistochemical analysis of immune cells infiltrate compared 
with untreated controls and those mice receiving Gardiquimod + SB5x treatment; 
the sections were stained with anti-CD4, anti-CD8, anti-F4/80 for macrophages and 
anti-neutrophils and the nuclear were counterstained with methyl green. 5D Effect 
of SB5x+Gard in tumor formation at early time points. The drugs (Gardiquimod 
1mg/kg and SB5x 10mg/kg) were injected at day 2 after tumor cell (Luc-MN/MCA1) 
inoculation. The tumor formation was monitored twice daily and at day 14, the 
luciferase activity was measured and photographed with IVIS® Imaging System (n=6 
in each treatment, 3 in each group were showed) 
 
Figure 6: analysis of Gardiquimod and TGF-β blockade on tumor angiogenesis 
6A Expression of NRP-1 and VEGF mRNA in vitro in response to Gard, SB5x and 
combine treatment. TAMs (3.8x105) and MN/MCA1 (3.8x104) were co-cultured in the 
presence of reagents for 24hrs and the expression of NRP-1 and VEGF was measured 
by Q-PCR. The drug concentration used was same as previously described for SB5x 
(5μM) and Gardiquimod (Gard, 5μg/ml). n=3 and the p value for the statistical 
significance is indicated in the graph. 6B CD31 Immunohistochemical staining in 
frozen tumor tissue sections for the control untreated and Gard+SB5x treated groups. 
The brown color showed the positive signals and the number was counted as shown 
in 6C 
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